vs
Innoviva, Inc.（INVA）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是Innoviva, Inc.的1.3倍（$151.1M vs $114.6M），Innoviva, Inc.同比增速更快（24.8% vs 3.6%），过去两年Innoviva, Inc.的营收复合增速更高（21.6% vs 5.1%）
Innoviva Inc是一家专注于呼吸道疾病、传染病及重症护理领域处方治疗药物研发、商业化及特许权使用费管理的医疗保健企业，与全球领先制药商合作，为北美、欧洲等核心市场的患者提供哮喘、慢性阻塞性肺疾病等病症的治疗方案。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
INVA vs RGR — 直观对比
营收规模更大
RGR
是对方的1.3倍
$114.6M
营收增速更快
INVA
高出21.2%
3.6%
两年增速更快
INVA
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.6M | $151.1M |
| 净利润 | $164.2M | — |
| 毛利率 | 66.0% | 17.8% |
| 营业利润率 | 34.0% | 2.3% |
| 净利率 | 143.2% | — |
| 营收同比 | 24.8% | 3.6% |
| 净利润同比 | 707.4% | — |
| 每股收益（稀释后） | $2.19 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INVARGR
| Q4 25 | $114.6M | $151.1M | ||
| Q3 25 | $107.8M | $126.8M | ||
| Q2 25 | $100.3M | $132.5M | ||
| Q1 25 | $88.6M | $135.7M | ||
| Q4 24 | $91.8M | $145.8M | ||
| Q3 24 | $89.5M | $122.3M | ||
| Q2 24 | $99.9M | $130.8M | ||
| Q1 24 | $77.5M | $136.8M |
净利润INVARGR
| Q4 25 | $164.2M | — | ||
| Q3 25 | $89.9M | $1.6M | ||
| Q2 25 | $63.7M | $-17.2M | ||
| Q1 25 | $-46.6M | $7.8M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $1.2M | $4.7M | ||
| Q2 24 | $-34.7M | $8.3M | ||
| Q1 24 | $36.5M | $7.1M |
毛利率INVARGR
| Q4 25 | 66.0% | 17.8% | ||
| Q3 25 | 70.1% | 15.1% | ||
| Q2 25 | 82.9% | 3.9% | ||
| Q1 25 | 82.7% | 22.0% | ||
| Q4 24 | 85.1% | 22.8% | ||
| Q3 24 | 81.6% | 18.5% | ||
| Q2 24 | 85.1% | 22.3% | ||
| Q1 24 | 77.5% | 21.5% |
营业利润率INVARGR
| Q4 25 | 34.0% | 2.3% | ||
| Q3 25 | 32.1% | -2.7% | ||
| Q2 25 | 48.6% | -15.6% | ||
| Q1 25 | 46.7% | 6.2% | ||
| Q4 24 | 47.0% | 7.8% | ||
| Q3 24 | 48.3% | 3.1% | ||
| Q2 24 | 54.7% | 6.9% | ||
| Q1 24 | 33.3% | 5.5% |
净利率INVARGR
| Q4 25 | 143.2% | — | ||
| Q3 25 | 83.4% | 1.2% | ||
| Q2 25 | 63.5% | -13.0% | ||
| Q1 25 | -52.6% | 5.7% | ||
| Q4 24 | 22.1% | — | ||
| Q3 24 | 1.4% | 3.9% | ||
| Q2 24 | -34.7% | 6.3% | ||
| Q1 24 | 47.1% | 5.2% |
每股收益（稀释后）INVARGR
| Q4 25 | $2.19 | $0.22 | ||
| Q3 25 | $1.08 | $0.10 | ||
| Q2 25 | $0.77 | $-1.05 | ||
| Q1 25 | $-0.74 | $0.46 | ||
| Q4 24 | $0.43 | $0.62 | ||
| Q3 24 | $0.02 | $0.28 | ||
| Q2 24 | $-0.55 | $0.47 | ||
| Q1 24 | $0.46 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $550.9M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $283.8M |
| 总资产 | $1.6B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INVARGR
| Q4 25 | $550.9M | $92.5M | ||
| Q3 25 | $476.5M | $80.8M | ||
| Q2 25 | $397.5M | $101.4M | ||
| Q1 25 | $319.1M | $108.3M | ||
| Q4 24 | $305.0M | $105.5M | ||
| Q3 24 | $260.6M | $96.0M | ||
| Q2 24 | $217.0M | $105.6M | ||
| Q1 24 | $178.4M | $115.3M |
股东权益INVARGR
| Q4 25 | $1.2B | $283.8M | ||
| Q3 25 | $1.0B | $279.6M | ||
| Q2 25 | $714.8M | $289.3M | ||
| Q1 25 | $646.9M | $321.5M | ||
| Q4 24 | $691.2M | $319.6M | ||
| Q3 24 | $668.5M | $314.9M | ||
| Q2 24 | $665.5M | $321.5M | ||
| Q1 24 | $703.7M | $332.0M |
总资产INVARGR
| Q4 25 | $1.6B | $342.0M | ||
| Q3 25 | $1.4B | $342.3M | ||
| Q2 25 | $1.3B | $349.5M | ||
| Q1 25 | $1.3B | $379.0M | ||
| Q4 24 | $1.3B | $384.0M | ||
| Q3 24 | $1.2B | $373.5M | ||
| Q2 24 | $1.2B | $376.7M | ||
| Q1 24 | $1.3B | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $54.5M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | — | $12.3M |
| 自由现金流率自由现金流/营收 | — | 8.2% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | 0.33× | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势，按日历期对齐
经营现金流INVARGR
| Q4 25 | $54.5M | $15.5M | ||
| Q3 25 | $49.7M | $12.9M | ||
| Q2 25 | $44.1M | $14.7M | ||
| Q1 25 | $48.6M | $11.1M | ||
| Q4 24 | $59.2M | $20.0M | ||
| Q3 24 | $48.7M | $9.4M | ||
| Q2 24 | $43.7M | $18.7M | ||
| Q1 24 | $37.0M | $7.3M |
自由现金流INVARGR
| Q4 25 | — | $12.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | $48.4M | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.6M |
自由现金流率INVARGR
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | 54.1% | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 4.1% |
资本支出强度INVARGR
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.3% | 5.5% | ||
| Q2 24 | 0.0% | 6.6% | ||
| Q1 24 | 0.0% | 1.3% |
现金转化率INVARGR
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.55× | 8.15× | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | 2.91× | — | ||
| Q3 24 | 40.14× | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | 1.01× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INVA
| Royalty | $54.9M | 48% |
| Xacduro | $32.1M | 28% |
| Giapreza | $19.6M | 17% |
| Xerava | $7.3M | 6% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
